𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized controlled trial of memantine in dementia associated with Parkinson's disease

✍ Scribed by Iracema Leroi; Ross Overshott; E. Jane Byrne; Emily Daniel; Alistair Burns

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
338 KB
Volume
24
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson's disease (PDD), an increasingly common complication of PD. This was a 22‐week trial of 25 participants with a DSM‐IV diagnosis of PDD who were randomized to either placebo or 20 mg/day of memantine. Memantine was well tolerated by participants at 20 mg/day dosing. No participant was withdrawn due to memantine‐related adverse events. Six weeks after drug withdrawal, a significantly greater proportion (P = 0.04) of memantine‐treated participants deteriorated globally compared with those treated with placebo. These findings suggest that continued treatment with memantine may be needed to maintain global level of functioning over time. Based on the findings of this pilot study, memantine is safe and very well‐tolerated in PDD. © 2009 Movement Disorder Society

📜 SIMILAR VOLUMES

Randomized placebo-controlled trial of d
Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease
✍ Iracema Leroi; Jason Brandt; Stephen G. Reich; Constantine G. Lyketsos; Stephen 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

## Abstract ## Objective To evaluate the efficacy and safety of donepezil, an acetylcholinesterase inhibitor, as a treatment for cognitive impairment and dementia in patients with Parkinson' s disease (PD). ## Methods Using a randomized, double‐blind, placebo‐controlled design, nine patients rec

The effect of memantine on sleep behavio
The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia
✍ Victoria Larsson; Dag Aarsland; Clive Ballard; Lennart Minthon; Elisabet Londos 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB 👁 2 views

## Abstract ## Objective Two common and characteristic sleep disturbances have been described in dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD); excessive daytime sleepiness and REM sleep behaviour disorder (RBD). This study is an analysis of a secondary outcome measure of

A randomized controlled trial of movemen
A randomized controlled trial of movement strategies compared with exercise for people with Parkinson's disease
✍ Meg E. Morris; Robert Iansek; Beth Kirkwood 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

## Abstract This randomized controlled clinical trial was conducted to compare the effects of movement rehabilitation strategies and exercise therapy in hospitalized patients with idiopathic Parkinson's disease. Participants were randomly assigned to a group that received movement strategy training

Current treatment of dementia with Lewy
Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease
✍ David J. Burn; Ian G. McKeith 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Dementia in Parkinson's disease (PDD) is a frequent and distressing complication with major consequences. Clinical and pathological features closely link PDD and dementia with Lewy bodies (DLB), suggesting they represent part of the same disease spectrum. Although dopaminergic deficiency primarily d

Cognitive correlates of visual hallucina
Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease
✍ Kolbjorn Bronnick; Murat Emre; Sibel Tekin; Siri B. Haugen; Dag Aarsland 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 1 views

## Abstract ## Background: There may be a relationship between cognitive impairment and visual hallucinations (VHs) in patients with Parkinson's disease (PD). The objective of this study was to compare the cognitive profile of hallucinating vs. nonhallucinating patients with Parkinson's disease de

Double-blind, randomized, controlled tri
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients
✍ Matthew B. Stern; Kenneth L. Marek; Joseph Friedman; Robert A. Hauser; Peter A. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 2 views

## Abstract Rasagiline (__N__‐propargyl‐1(__R__)‐aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase‐B inhibitor. This study was designed to evaluate the safety, tolerability, and preliminary efficacy of rasagiline monotherapy in early Parkinson's disease (PD) patients n